Share This

Public company info - Mabpharm Limited , 02181.HK
Input the stock code or the company name     Search  
 
 Profile   Information   Data   Financial Ratios   Profit Loss   Cash Flow   Balance   Earnings   Dividend 

Mabpharm Limited, 02181.HK - Company Profile
Chairman Jiao Shuge
Share Issued (share) 4,124,000,000
Par Currency U.S. Dollar
Par Value 1.0E-4
Industry Biotechnology
Corporate Profile Business Summary: The group is a leading biopharmaceutical company in China, focusing on the research, development and production of new drugs and biosimilar for cancers and autoimmune diseases. Performance for the year: The Group’s loss attributable to shareholders for the year ended 31-12-2019 amounted to RMB 202.5 million. Basic loss per share was RMB 0.05. Business Review The group strive to bring to market high quality and affordable innovative biologics through the group’s efficient R&D system and low-cost pharmaceutical production capability, and develop differentiated therapeutic products by fully utilizing the group’s extensive R&D experience. the group’s pipeline of drug candidates currently consists of 11 monoclonal antibody drugs and one strong antibody drug, three of which are the group’s Core Products: CMAB008 (infliximab): completed clinical trial and is in the process of new drug marketing application. the group have launched the “Phase I comparative study of randomized, double-blind, parallel-controlled, single-dose pharmacokinetics, safety and immunogenicity of CMAB008 and infliximab for injection in healthy male volunteers”, which is expected to be directly admitted to the markets for treating (i) rheumatoid arthritis, (ii) adult and pediatric patients with Crohn’s disease, (iii) patients with fistulizing Crohn’s disease, (iv) ankylosing spondylitis, (v) psoriasis and (vi) adult patients with ulcerative colitis; CMAB007 (omalizumab): currently under phase III clinical trials; CMAB009 (cetuximab): currently under phase III clinical trials (together, the “Core Products”). Among the group’s other drug candidates, CMAB809 (trastuzumab) completed phase I clinical trial and CMAB819 (nivolumab) will soon be put into clinical trials. The latest research results show that CMAB816 developed by us has a sound prospect in the treatment and prevention of tumors, especially lung cancer, as such the group will give priority to the development of CMAB816. In addition, the group also successfully developed a new “strong antibody” drug CMAB017 for treating cancer. It is expected that CMAB017 will have better safety and efficacy in treating tumors than other similar antibody drugs. The group have strong in-house capabilities in pharmaceutical research, pre-clinical and clinical development, and manufacturing, and are building the group’s sales and marketing team to prepare for the commercialization of the group’s product candidates. the group focus on the R&D of monoclonal antibodies. the group’s core R&D team members have more than 16 years of experience in this area, and have led three major projects under the “863” Program, among other national-level scientific research projects. In addition, one of the group’s core R&D team members is also a member of the 11th Session of the Chinese Pharmacopoeia Commission. the group’s production site in Taizhou, currently equipped with a 3×1,500L monoclonal antibody bioreactor system, is one of the largest antibody drug production facilities in China in terms of production capacity. The group believe that the group are well positioned to seize China’s substantial market opportunities, in particular those resulting from China’s recent healthcare regulatory reforms, including new medical insurance measures. The primary focus of the group’s R&D – monoclonal antibody drugs targeting cancers and autoimmune diseases – has substantial untapped clinical demand in China. With the current pandemic caused by 2019 Novel Coronavirus (“COVID-19”), the group have newly developed a recombinant bispecific fusion protein, CMAB020, which is expected to be used for prevention and treatment of SARS-CoV/-2 (SARS-CoV and SARS-CoV-2) infections and SARS/ COVID-19 diseases (pneumonia caused by SARS-CoV/-2). the group have submitted a patent application for the invention of CMAB020 to China National Intellectual Property Administration on March 23, 2020 (Application No.: 202010208906.8/PCT No.: PCT/CN2020/080859). The drug consists of two functional arms, one of which has an antibody that targets the spike protein of coronavirus and the other consists of a protein which can preserve enzyme activity to reduce vasoconstriction and increase blood flow to the infected lung tissue. It is expected that the drug can effectively treat pneumonia caused by SARS-CoV and SARS-CoV-2, and reduce lung inflammation and cytokine storms. At present, the Company has completed the lab-scale preparation and in vitro function evaluation of CMAB020, and will commence the in vivo experiment for further technical evaluation. Prospects: Continue to advance the clinical research and commercialization of the group’s drug candidates Over the short-term, the group intend to focus on completing clinical trials and the eventual commercialization of the group’s current pipeline of drug candidates, particularly the group’s Core Products, CMAB007, CMAB009 and CMAB008. To bring the group’s Core Products to market, the group aim to reinforce the group’s R&D teams, particularly the clinical medicine team, through the provision of regular professional training and pushing ahead with the clinical trials for CMAB007, CMAB009 and CMAB008. the group are also in the process of establishing a sales team consisting of staff with strong academic promotion experience and capabilities. the group’s goal is to generate stable revenue and profits in the future by creating the group’s own sales team in China and strengthening the group’s commercialization capabilities by further building the group’s sales team. Continue to maintain investments in advanced technologies and product development The group believe R&D is the key element to support the group’s future growth and the group’s ability to maintain the group’s competitiveness in a global biopharmaceutical market. the group plan to upgrade the development of the group’s integrated technological platforms from molecular design to commercialized production, and focus on the R&D of biologics with huge clinical demand and the potential for sustained and rapid growth in China. In order to capture new opportunities in the biopharmaceutical market, the group plan to continue increasing the group’s investment into innovative technologies for the development of drugs with improved curative effects and less toxic side effects in order to maintain the group’s industry leading position. the group also expect to invest in talent to expand and enhance the group’s R&D team. Continue to attract and nurture high quality talent to support the group’s rapid growth Recruiting and retaining high quality scientific and technological talent as well as other leaders in R&D technology will be key to the group’s success. the group plan to leverage the group’s close cooperation with elite universities in China and internationally to recruit and develop outstanding R&D personnel. the group also plan to provide systematic and sophisticated training and development programs to the group’s research teams in order to enhance and optimize their scientific and technical abilities to benefit the group’s Company. Part of this strategy involves the creation of an incentive scheme to retain and motivate high-performing team members. Establish global brand awareness and foster deeper and more extensive cooperative relationship with domestic and overseas renowned pharmaceutical companies To build the group’s brand internationally and to support the group’s sustainable growth, the group plan to in-license products from global pharmaceutical companies for sales in China and/or to transfer or out-license overseas product rights of certain of the group’s drug candidates to other pharmaceutical companies. the group may also consider developing collaborative partnerships with global pharmaceutical companies in order to enter and expand the group’s market share in markets outside of China and to further broaden the geographic coverage of the group’s business. As part of this strategy, the group may take advantage of strategic opportunities for merger and acquisition internationally to expand the group’s pipeline of products for R&D development and sales in overseas markets.

Information from the financial statements of listed companies

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2024Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.